Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie · 2025
Cataract surgery in eyes with adult-onset foveomacular-vitelliform dystrophy.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Shmueli Or, Batash Tomer, Nitzan Itay, Chowers Itay, Tiosano Liran
Аннотация
PURPOSE: To assess the outcomes and safety of cataract surgery in Adult-Onset Foveomacular-Vitelliform dystrophy (AFVD) patients.
METHODS: This retrospective study analyzed eyes with AFVD that underwent cataract surgery in a tertiary center, comparing them with eyes affected by none and neovascular age-related macular degeneration (NVAMD). Data included demographics, best-corrected visual acuity LogMAR (VA), eye examination results, and optical coherence tomography (OCT) results. The primary outcome was improvement in VA. A secondary outcome was AFVD progression such as the development of choroidal neovascularization (CNV) or retinal atrophy.
RESULTS: The cohort included 83 eyes (18 with AFVD, 27 with none-NV AMD, and 38 with NVAMD). AFVD eyes showed significant improvement in VA±SD from pre-surgery (0.60 ± 0.34) to 1 month (0.23 ± 0.11; P < 0.0001) and 12 months post-operatively (0.26 ± 0.12; P < 0.0001). No cases of CNV or major AFVD progression changes were observed over 12 months of follow up. However, at last follow-up (62.20 ± 39.30 months) there was increased proportion of atrophic AFVD (44.40% compared to 5.50% at baseline; P = 0.10). No difference was found comparing VA improvement one month after surgery of none-NV AMD, NVAMD and AFVD (AFVD = 0.37 ± 0.36, none-NV AMD = 0.47 ± 0.68, NVAMD = 0.28 ± 0.37; P = 0.29). In the none-NV AMD group, one eye developed CNV ten months post-operatively and another eye demonstrated worsening retinal atrophy one-month post-surgery. In the NVAMD group, 9 eyes developed retinal atrophy at last follow up.
CONCLUSION: Cataract surgery in AFVD eyes led to significant visual acuity improvement and demonstrated good safety with no new CNV or retinal atrophy. The similar visual improvement across the AFVD, none-NV AMD and NVAMD groups suggests the procedure's efficacy and safety for AFVD patients.
METHODS: This retrospective study analyzed eyes with AFVD that underwent cataract surgery in a tertiary center, comparing them with eyes affected by none and neovascular age-related macular degeneration (NVAMD). Data included demographics, best-corrected visual acuity LogMAR (VA), eye examination results, and optical coherence tomography (OCT) results. The primary outcome was improvement in VA. A secondary outcome was AFVD progression such as the development of choroidal neovascularization (CNV) or retinal atrophy.
RESULTS: The cohort included 83 eyes (18 with AFVD, 27 with none-NV AMD, and 38 with NVAMD). AFVD eyes showed significant improvement in VA±SD from pre-surgery (0.60 ± 0.34) to 1 month (0.23 ± 0.11; P < 0.0001) and 12 months post-operatively (0.26 ± 0.12; P < 0.0001). No cases of CNV or major AFVD progression changes were observed over 12 months of follow up. However, at last follow-up (62.20 ± 39.30 months) there was increased proportion of atrophic AFVD (44.40% compared to 5.50% at baseline; P = 0.10). No difference was found comparing VA improvement one month after surgery of none-NV AMD, NVAMD and AFVD (AFVD = 0.37 ± 0.36, none-NV AMD = 0.47 ± 0.68, NVAMD = 0.28 ± 0.37; P = 0.29). In the none-NV AMD group, one eye developed CNV ten months post-operatively and another eye demonstrated worsening retinal atrophy one-month post-surgery. In the NVAMD group, 9 eyes developed retinal atrophy at last follow up.
CONCLUSION: Cataract surgery in AFVD eyes led to significant visual acuity improvement and demonstrated good safety with no new CNV or retinal atrophy. The similar visual improvement across the AFVD, none-NV AMD and NVAMD groups suggests the procedure's efficacy and safety for AFVD patients.